Zelluna, a developer of allogeneic ‘off the shelf’ T cell receptor based natural killer (TCR-NK) cells for the treatment of cancer, has announced the successful completion of a Business Combination and Private Placement on the Oslo Stock Exchange. 

The share capital increases relating to the issuance of the Consideration Shares and the Private Placement Shares was registered on 3 March 2025 with the Norwegian Register of Business Enterprises.  

The new share capital of the company is now NOK 20,227,065.30 ($1.8 million) divided into 202,270,653 shares, each with a nominal value of NOK 0.10. 

The name change from Ultimovacs to Zelluna has also been registered with the Norwegian Register of Business Enterprises. The ticker code of the company will change from ULTI to ZLNA. 

Zelluna aims to take the curative potential of cell therapies to solid cancers at a global scale. Its ‘off the shelf’ cell therapy platform merges clinically validated components – TCR targeting with NK cells – to form TCR-NK.  

The lead asset nearing the clinic is the first MAGE-A4 targeting TCR-NK, which the company says can potentially be used to treat a range of solid cancers with unmet medical need in high value cancer markets.   

Namir Hassan, the Chief Executive Officer of Zelluna ASA, commented: “Through the unwavering dedication of our team, board and investors, we have pioneered the TCR-NK platform from basic research, to the public markets with an exciting, worlds first MAGE-A4 lead program heading towards the clinic. Listing on the Oslo Stock Exchange opens new doors for growth and innovation, enhances our visibility and provides the financial flexibility needed to accelerate the development of our groundbreaking cell therapies getting them closer to solid cancer patients who need them.”

Diana Spencer, Senior Digital Content Editor, DDW